CONCLUSION
DEL DLBCL, DLBCL
DEL
In this trial, upfront patients demonstrated significantly better 3‐year OS and PFS. It is a relatively small period, and further follow‐up is needed to confirm the sustainability of our result. The significant difference in early relapse rate and the same tendency in all relapse rates in favor of upfront auto‐HSCT is promising.We suggest, that upfront auto‐HSCT can serve as a familiar and adequate option to significantly improve a prognosis in young high‐risk patients with DEL DLBCL. This clinical implication does not require special additions and can be used in any HSCT unit. However, prospective randomized trials are needed to confirm the significance of DEL in this cohort.In summary, upfront HDCT with auto‐HSCT can be a possible treatment option in DLBCL NOS, age 18–65, stage IV, IPI ≥2 patients.